The tweet was deleted by the author.
But we saved everything 🙂.
CVRx announced that Dr. Philip Seibel and the team at Lawnwood Medical Center have successfully completed their 15th Barostim implant.
This milestone reflects sustained efforts to provide innovative therapy options for patients with heart failure. Barostim therapy is designed to improve patient outcomes by targeting cardiovascular health through advanced implant technology. CVRx continues to support medical teams in their adoption and deployment of new solutions for chronic conditions.
CVRx previously presented Barostim device therapy at ACC26, highlighting its aim to improve exercise capacity for heart failure patients beyond standard GDMT here. The company also forecast preliminary Q1 2026 revenue between $14.7 million and $14.8 million, projecting 20 percent growth from the prior year period here. These developments reflect CVRx’s ongoing expansion of both its clinical innovations and financial footprint.